Heterocyclic aspartyl protease inhibitors

US7700603B2 · kind B2 · utility

Assignee

• SCHERING CORPORATION · US

Inventors

• Zhaoning Zhu · Plainsboro, US
• Brian McKittrick · New Vernon, US
• Zhong-Yue Sun · Sayreville, US
• Yuanzan C. Ye · New Brunswick, US
• Johannes H. Voigt · Cranford, US
• Corey Strickland · Bound Brook, US
• Elizabeth M. Smith · Verona, US
• Andrew Stamford · Madison, US
• William J. Greenlee · Teaneck, US
• Robert Mazzola · Stewartsville, US
• John P. Caldwell · Ringwood, US
• Jared N. Cumming · Garwood, US
• Lingyan Wang · East Brunswick Township, US
• Yusheng Wu · New York, US
• Ulrich Iserloh · Hoboken, US
• Tao Guo
• Thuy X. H. Le · Monmouth Junction, US
• Kurt W. Saionz · Cranford, US
• Suresh D. Babu · Pennington, US
• Rachael C. Hunter · Princeton, US
• Michelle L. Morris · Lawrenceville, US
• Gang Qian · Kendall Park, US
• Dawit Tadesse · Avenel, US

Key dates

• Filing date: Jun 9, 2005
• Grant date: Apr 20, 2010
• Expiry date: Nov 16, 2026

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/06
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Disclosed are compounds of the formula Ior a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes.Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or m2 antagonist.